MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)

Metastatic castration resistant prostate cancer

Radiographic Progression-free Survival (rPFS), Overall Survival (OS)

Time to Initiation of the First Subsequent Anticancer Therapy (TFST), Objective Response Rate (ORR), Duration of Response (DOR), Time to Pain Progression (TTPP), Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G) Total Score, Time to Deterioration (TTD) in FACT-G Total Score, Overall Improvement in FACT-G Total Score, Time to Prostate-specific Antigen (PSA) progression, Prostate-specific Antigen (PSA) Response Rate, Time to first symptomatic skeletal-related event (TSSRE), Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE

No related papers found yet.

Papers published before 2008-02-04 may not appear yet. Historical indexing is in progress.

Czechia, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Portugal, Romania, Slovakia, Spain, Sweden